logo (1).png
Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma
12 mars 2024 02h30 HE | Vidac Pharma Holding PLC
London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
Vidac Pharma annonce
Vidac Pharma annonce des données positives de l'analyse intermédiaire de phase 2a pour son produit phare VDA-1102 dans le traitement des Lymphomes T cutanés (LCT), une maladie rare.
29 janv. 2024 02h00 HE | Vidac Pharma Holding PLC
London (UK), January 29, 2024 - Vidac Pharma Holdings Plc. (Hambourg et Stuttgart : T9G ; ISIN:GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, pionnière d'une...
Vidac Pharma reports
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
29 janv. 2024 02h00 HE | Vidac Pharma Holding PLC
London (UK), January 29, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking...
GMILogo_Vertical-Gradient.png
Photopheresis Products Market to exceed USD 488 billion by 2032, says Global Market Insights Inc.
27 juin 2023 07h00 HE | Global Market Insights Inc.
Selbyville, Delaware, June 27, 2023 (GLOBE NEWSWIRE) -- Photopheresis Products Market size is predicted to surpass USD 488 billion by 2032. Advancements in medical technology and increasing demand...
Research Nester  Logo
Global Cutaneous T-cell Lymphoma (CTCL) Treatment Market to be Driven by Rising Prevalence of Lymphoma Cancer and Growing Advances in Cancer Treatment at a CAGR of ~5% over 2022-2030
15 juil. 2022 10h47 HE | Research Nester
New York, July 15, 2022 (GLOBE NEWSWIRE) -- The different types of cancer that arise in the immune cells, also known as lymphocytes, are commonly termed as lymphoma. It is estimated that in the...
FBI LOGO TM.png
North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Size [2022-2028] | to Reach USD 587.4 Million, at a CAGR 13.6%
16 févr. 2022 05h48 HE | Fortune Business Insights
Pune, India, Feb. 16, 2022 (GLOBE NEWSWIRE) -- North America cutaneous T-cell lymphoma (CTCL) therapeutics market size is projected to hit an annual valuation of USD 587.4 million by 2028,...
logo long.jpg
Global T-cell Lymphoma Market to Surpass US$ 2,495.4 Million by 2028, Says Coherent Market Insights (CMI)
20 déc. 2021 09h00 HE | CMI
SEATTLE, Dec. 20, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global T-cell lymphoma market is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to...
Global Cutaneous T-cell Lymphoma Market is projected to be worth USD 3531.5 Million by 2030 I SPER Market Research
30 nov. 2021 12h07 HE | SPER Market Research Pvt. Ltd.
New York, Nov. 30, 2021 (GLOBE NEWSWIRE) -- The global cutaneous T-cell Lymphoma market is expected to grow at a CAGR of 8.56% from 2020 to reach USD 3531.5 billion by 2030. The growth is primarily...
Logo.png
Promising Treatment for Cutaneous T-cell Lymphoma Enters Clinical Trials
03 août 2021 20h00 HE | DelveInsight Business Research LLP
Los Angeles, USA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Cutaneous T-cell Lymphoma Enters Clinical Trials   Around 25+ key companies are developing Cutaneous T-Cell Lymphoma...
rhL
Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)
09 avr. 2018 07h00 HE | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 09, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...